Evidence-Based Approach to Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

Authors

J Drew Payne
Kimberly Sims
Cynthia Peacock
Tanis Welch
Ruth E Berggren

Language

English

Publication Date

6-4-2021

Journal

Baylor University Medical Center Proceedings

DOI

10.1080/08998280.2021.1925049

PMID

34211257

PMCID

PMC8182819

PubMedCentral® Posted Date

6-4-2021

PubMedCentral® Full Text Version

Post-print

Abstract

Misinformation and promotion of well-intended but disproved therapies for COVID-19 have plagued evidence-based shared decision-making throughout the COVID-19 pandemic. In times of crisis, clinicians may feel that their strong inclination to prescribe potentially harmful, unproven therapies on behalf of their patients is supported by beneficence. Clinicians should mindfully identify and avoid commission bias during this pandemic, especially as more data have accumulated to assist with clinically sound decision-making. We describe a more evidence-based approach to treatment of early outpatient COVID-19, stressing the availability of Food and Drug Administration emergency use authorization therapies and considering plausibly beneficial, nonprescription supplements that are generally regarded as safe.

Keywords

colchicine, COVID-19, evidence-based, ivermectin, melatonin, outpatient therapy, SARS-CoV-2

Published Open-Access

yes

Recommended Citation

Payne, J Drew; Sims, Kimberly; Peacock, Cynthia; et al., "Evidence-Based Approach to Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection" (2021). Faculty and Staff Publications. 799.
https://digitalcommons.library.tmc.edu/baylor_docs/799